These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7526970)

  • 1. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies.
    Van de Voorde WM; Elgamal AA; Van Poppel HP; Verbeken EK; Baert LV; Lauweryns JM
    Cancer; 1994 Dec; 74(12):3164-75. PubMed ID: 7526970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate.
    Van de Voorde WM; Van Poppel HP; Verbeken EK; Oyen RH; Baert LV; Lauweryns JM
    Mod Pathol; 1995 Aug; 8(6):591-8. PubMed ID: 8532689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report.
    Nishiyama T; Terunuma M
    Int J Urol; 1994 Dec; 1(4):355-6. PubMed ID: 7542158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2006 Aug; 30(8):980-5. PubMed ID: 16861969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
    Roessler W; Hinke A; Wieland WF
    Urology; 1994 Feb; 43(2 Suppl):57-60. PubMed ID: 8116134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases.
    Adlakha H; Bostwick DG
    Hum Pathol; 1994 Feb; 25(2):135-9. PubMed ID: 7509774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
    Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
    J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological effects of androgen deprivation in prostatic cancer.
    Civantos F; Soloway MS; Pinto JE
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
    Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
    Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.
    Têtu B; Srigley JR; Boivin JC; Dupont A; Monfette G; Pinault S; Labrie F
    Am J Surg Pathol; 1991 Feb; 15(2):111-20. PubMed ID: 1989458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
    Armas OA; Aprikian AG; Melamed J; Cordon-Cardo C; Cohen DW; Erlandson R; Fair WR; Reuter VE
    Am J Surg Pathol; 1994 Oct; 18(10):979-91. PubMed ID: 7522415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of neoadjuvant androgen deprivation therapy on prostatic cancer.
    Polito M; Muzzonigro G; Minardi D; Montironi R
    Eur Urol; 1996; 30 Suppl 1():26-31; discussion 38-9. PubMed ID: 8977987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
    Krupski T; Petroni GR; Frierson HF; Theodorescu JU
    Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
    Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.